Maurice Horsten

Maurice Horsten (1967) has a distinguished career in pharmaceuticals, medical devices, and biotechnology. He has worked for multinational companies like Eli Lilly & Company and Mediq NV in various countries and has also been a successful entrepreneur. In 2006, he and his business partner sold medical device supplier DiabetesDirect to Mediq NV. Later, he was an investor and CEO of PharmaCell, a biotech company in regenerative medicine, which was successfully sold to Lonza SA. Currently, Maurice is the Director of the NV Bossche Investment Company (BIM), where he has extensive experience managing public investment companies and established the Bossche Investment Fund (BIF). As a board member of Braventure, he has worked on enhancing the start-up ecosystem. He also served on the board of the Limburg University Fund for nearly 10 years.

In the life sciences sector, Maurice serves on the supervisory boards of Brabant Life Sciences Seed Fund and Basic Pharma BV. For the province of Brabant, he is the chairman of the Leisure Development Fund Brabant, the supervisory board of NV Monumenten Beheer Brabant, and a member of the supervisory board of Van Gogh Sites NV. He is honored to contribute to RegMed XB’s Supervisory Board, supporting the growth of regenerative medicine, which he sees as having great potential.